专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

CA2413768A1 PHARMACEUTICAL COMPOSITIONS FOR ANGIOGENIC THERAPY 未知
公开(公告)号：CA2413768A1
公开(公告)日：2002-01-03
申请号：CA2413768
申请日：2001-06-27
申请人： ANGES MG INC , MORISHITA RYUICHI
发明人： AOKI MOTOKUNI , MORISHITA RYUICHI , KOIKE HIROMI , TANABE TADASHI
IPC分类号： A61K31/5585 , A61K31/711 , A61K38/17 , A61K38/52 , A61K48/00 , A61P9/00 , A61P9/10 , A61K45/00 , A61K38/18
摘要： Medicinal compositions for angiogenic therapy which contain as the active ingredients at least one member selected from among substances having a vasodilating effect and/or a platelet aggregation inhibitory effect and substances producing the same, and a gene encoding an angiogenesis factor; agents for potentiating the angiogenic effect of a gene encoding an angiogenesis factor which contain as the active ingredient at least one memb er selected from among substances having a vasodilating effect and/or a platele t aggregation inhibitory effect and substances producing the same; an angiogen ic agent which contains prostacyclin synthase gene as the active ingredient; medicinal compositions for angiogenic therapy which contain ets-1 gene and another gene encoding an angiogenesis factor as the active ingredients; an agent for potentiating the angiogenic effect of a gene encoding an angiogenesis factor which contain ets-1 gene as the active ingredient; and a n angiogenic agent which contains ets-1 gene as the active ingredient.

2. 发明专利

AT530197T 未知
公开(公告)号：AT530197T
公开(公告)日：2011-11-15
申请号：AT07021738
申请日：2001-06-27
申请人： ANGES MG INC , MORISHITA RYUICHI
发明人： MORISHITA RYUICHI , KOIKE HIROMI , TANABE TADASHI , AOKI MOTOKUNI
IPC分类号： A61K45/00 , A61K31/5585 , A61K31/711 , A61K38/16 , A61K38/17 , A61K38/18 , A61K38/52 , A61K48/00 , A61P9/00 , A61P9/10
摘要： The present invention provides: (1) pharmaceutical compositions for angiogenic therapy which contain, as the active ingredients, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect, and substances producing them; and a gene encoding an angiogenesis factor; (2) agents for potentiating the angiogenic effect of a gene encoding an angiogenesis factor that contain, as the active ingredient, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect and substances producing them; (3) an angiogenic agent which contains a prostacyclin synthase gene as the active ingredient; (4) pharmaceutical compositions for angiogenic therapy which contain ets-1 gene and another gene encoding an angiogenesis factor as the active ingredients; (4) an agent which contain ets-1 gene as the active ingredient for potentiating the angiogenic effect of another gene encoding an angiogenesis factor; and (5) an angiogenic agent which contains ets-1 gene as the active ingredient.

3. 发明专利

DE60134021D1 未知
公开(公告)号：DE60134021D1
公开(公告)日：2008-06-26
申请号：DE60134021
申请日：2001-06-27
申请人： ANGES MG INC , MORISHITA RYUICHI
发明人： MORISHITA RYUICHI , KOIKE HIROMI , TANABE TADASHI , AOKI MOTOKUNI
IPC分类号： A61K45/00 , A61K31/5585 , A61K31/711 , A61K38/17 , A61K38/43 , A61K38/52 , A61K48/00 , A61P9/00 , A61P9/10 , C12N15/19 , C12N15/52
摘要： The present invention provides: (1) pharmaceutical compositions for angiogenic therapy which contain, as the active ingredients, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect, and substances producing them; and a gene encoding an angiogenesis factor; (2) agents for potentiating the angiogenic effect of a gene encoding an angiogenesis factor that contain, as the active ingredient, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect and substances producing them; (3) an angiogenic agent which contains a prostacyclin synthase gene as the active ingredient; (4) pharmaceutical compositions for angiogenic therapy which contain ets-1 gene and another gene encoding an angiogenesis factor as the active ingredients; (4) an agent which contain ets-1 gene as the active ingredient for potentiating the angiogenic effect of another gene encoding an angiogenesis factor; and (5) an angiogenic agent which contains ets-1 gene as the active ingredient.

4. 发明专利

AU2001266338B2 Medicinal compositions for angiogenic therapy 未知
公开(公告)号：AU2001266338B2
公开(公告)日：2006-11-09
申请号：AU2001266338
申请日：2001-06-27
申请人： ANGES MG INC , MORISHITA RYUICHI
发明人： AOKI MOTOKUNI , KOIKE HIROMI , TANABE TADASHI , MORISHITA RYUICHI
IPC分类号： A61K45/00 , A61K31/5585 , A61K31/711 , A61K38/17 , A61K38/52 , A61K48/00 , A61P9/00 , A61P9/10
摘要： The present invention provides: (1) pharmaceutical compositions for angiogenic therapy which contain, as the active ingredients, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect, and substances producing them; and a gene encoding an angiogenesis factor; (2) agents for potentiating the angiogenic effect of a gene encoding an angiogenesis factor that contain, as the active ingredient, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect and substances producing them; (3) an angiogenic agent which contains a prostacyclin synthase gene as the active ingredient; (4) pharmaceutical compositions for angiogenic therapy which contain ets-1 gene and another gene encoding an angiogenesis factor as the active ingredients; (4) an agent which contain ets-1 gene as the active ingredient for potentiating the angiogenic effect of another gene encoding an angiogenesis factor; and (5) an angiogenic agent which contains ets-1 gene as the active ingredient.

5. 发明专利

AT395071T 未知
公开(公告)号：AT395071T
公开(公告)日：2008-05-15
申请号：AT01943840
申请日：2001-06-27
申请人： ANGES MG INC , MORISHITA RYUICHI
发明人： MORISHITA RYUICHI , KOIKE HIROMI , TANABE TADASHI , AOKI MOTOKUNI
IPC分类号： A61K38/18 , A61K31/5585 , A61K31/711 , A61K38/17 , A61K38/43 , A61K38/52 , A61K48/00 , A61P9/00 , A61P9/10 , C12N15/19 , C12N15/52
摘要： The present invention provides: (1) pharmaceutical compositions for angiogenic therapy which contain, as the active ingredients, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect, and substances producing them; and a gene encoding an angiogenesis factor; (2) agents for potentiating the angiogenic effect of a gene encoding an angiogenesis factor that contain, as the active ingredient, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect and substances producing them; (3) an angiogenic agent which contains a prostacyclin synthase gene as the active ingredient; (4) pharmaceutical compositions for angiogenic therapy which contain ets-1 gene and another gene encoding an angiogenesis factor as the active ingredients; (4) an agent which contain ets-1 gene as the active ingredient for potentiating the angiogenic effect of another gene encoding an angiogenesis factor; and (5) an angiogenic agent which contains ets-1 gene as the active ingredient.

6. 发明专利

AU2001266338B8 Pharmaceutical compositions for angiogenic therapy 未知
公开(公告)号：AU2001266338B8
公开(公告)日：2006-12-14
申请号：AU2001266338
申请日：2001-06-27
申请人： ANGES MG INC , MORISHITA RYUICHI
发明人： AOKI MOTOKUNI , KOIKE HIROMI , TANABE TADASHI , MORISHITA RYUICHI
IPC分类号： A61K31/5585 , A61K31/711 , A61K38/17 , A61K38/52 , A61K48/00 , A61P9/00 , A61P9/10
摘要： The present invention provides: (1) pharmaceutical compositions for angiogenic therapy which contain, as the active ingredients, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect, and substances producing them; and a gene encoding an angiogenesis factor; (2) agents for potentiating the angiogenic effect of a gene encoding an angiogenesis factor that contain, as the active ingredient, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect and substances producing them; (3) an angiogenic agent which contains a prostacyclin synthase gene as the active ingredient; (4) pharmaceutical compositions for angiogenic therapy which contain ets-1 gene and another gene encoding an angiogenesis factor as the active ingredients; (4) an agent which contain ets-1 gene as the active ingredient for potentiating the angiogenic effect of another gene encoding an angiogenesis factor; and (5) an angiogenic agent which contains ets-1 gene as the active ingredient.

7. 发明公开

EP1300158A4 MEDICINAL COMPOSITIONS FOR ANGIOGENIC THERAPY 有权
标题翻译：药物组合物用于血管生成治疗
公开(公告)号：EP1300158A4
公开(公告)日：2005-04-13
申请号：EP01943840
申请日：2001-06-27
申请人： ANGES MG INC , MORISHITA RYUICHI
发明人： MORISHITA RYUICHI , KOIKE HIROMI , TANABE TADASHI , AOKI MOTOKUNI
IPC分类号： A61K31/5585 , A61K31/711 , A61K38/17 , A61K38/52 , A61K48/00 , A61P9/00 , A61P9/10 , A61K45/00 , A61K38/18
CPC分类号： A61K38/52 , A61K31/5585 , A61K31/711 , A61K38/1709 , A61K38/1833 , A61K38/1858 , A61K48/00 , A61K2300/00
摘要： Medicinal compositions for angiogenic therapy which contain as the active ingredients at least one member selected from among substances having a vasodilating effect and/or a platelet aggregation inhibitory effect and substances producing the same, and a gene encoding an angiogenesis factor; agents for potentiating the angiogenic effect of a gene encoding an angiogenesis factor which contain as the active ingredient at least one member selected from among substances having a vasodilating effect and/or a platelet aggregation inhibitory effect and substances producing the same; an angiogenic agent which contains prostacyclin synthase gene as the active ingredient; medicinal compositions for angiogenic therapy which contain ets-1 gene and another gene encoding an angiogenesis factor as the active ingredients; an agent for potentiating the angiogenic effect of a gene encoding an angiogenesis factor which contain ets-1 gene as the active ingredient; and an angiogenic agent which contains ets-1 gene as the active ingredient.

8. 发明专利

JP2012025759A Medicinal composition for angiogenic therapy 有权
标题翻译：药物治疗用药物组合物
公开(公告)号：JP2012025759A
公开(公告)日：2012-02-09
申请号：JP2011190400
申请日：2011-09-01
申请人： Anges Mg Inc , Ryuichi Morishita , アンジェスMg株式会社 , 竜一森下
发明人： MORISHITA RYUICHI , KOIKE HIROMI , TANABE TADASHI , AOKI MOTOKUNI
IPC分类号： A61K45/00 , A61K48/00 , A61P7/02 , A61P9/10 , A61P9/14 , A61P43/00
摘要： PROBLEM TO BE SOLVED: To provide a new medicinal composition for angiogenic therapy.SOLUTION: The present invention discloses the medicinal composition for the angiogenic therapy containing, as effective components, at least one kind selected from the group comprising substances having a vasodilation effect and/or a platelet aggregation restraining effect, and substances generating the substances, and a gene encoding an angiogenesis factor. an enhancement agent for an angiogenic effect by a gene of encoding the angiogenesis factor, containing, as the effective components, at least one kind selected from the group comprising the substances having the vasodilation effect and/or the platelet aggregation restraining effect, and the substances generating the substances, an angiogenic medicine containing a prostacyclin synthetase gene as an active component, the medicinal composition for the angiogenic therapy containing an ets-1 gene and other gene encoding the angiogenesis factor as effective components, an enhancement agent for the angiogenic effect by the other gene encoding the angiogenesis factor, containing the ets-1 gene as the effective component, and an angiogenic medicine containing the ets-1 gene as an effective component.
摘要翻译：要解决的问题：提供用于血管生成治疗的新药物组合物。解决方案：本发明公开了用于血管生成治疗的药物组合物，其含有选自包含具有血管舒张作用和/或血小板聚集抑制作用的物质的组中的至少一种作为有效成分，以及产生该物质的物质，以及编码血管生成因子的基因。包含编码血管生成因子的基因的血管生成作用的增强剂，其含有选自包含具有血管舒张作用和/或血小板聚集抑制作用的物质的组中的至少一种作为有效成分，以及所述物质生成含有前列环素合成酶基因作为活性成分的血管生成药物，含有ets-1基因的血管发生疗法的药物组合物和编码血管生成因子的其他基因作为有效成分，作为血管生成作用的增效剂含有ets-1基因作为有效成分的编码血管生成因子的其他基因，以及含有ets-1基因作为有效成分的血管生成药。版权所有（C）2012，JPO＆INPIT

9. 发明专利

JP2005120069A Inflammatory disease-treating agent 审中-公开
标题翻译：炎症性疾病治疗剂
公开(公告)号：JP2005120069A
公开(公告)日：2005-05-12
申请号：JP2004049299
申请日：2004-02-25
申请人： Anges Mg Inc , アンジェスMg株式会社
发明人： HATAE TOSHIHISA , YOKOYAMA CHIEISHI , TANABE TADASHI
IPC分类号： A61K45/00 , A61K31/00 , A61K31/557 , A61K31/5585 , A61K31/7088 , A61K38/00 , A61K48/00 , A61P29/00 , C12N9/90
CPC分类号： A61K31/00 , A61K31/557 , A61K48/005 , C12N9/90
摘要： PROBLEM TO BE SOLVED: To provide an elucidation of a target gene of a PGI2-PPARδ transmission system and a new inflammatory disease-treating agent by taking the PGI2-PPARδ transmission system as the target.
SOLUTION: This target of the PG (prostaglandin) I2-PPAR (peroxisome proliferator-activated receptor) δ transmission system is found to be an IL (interleukin)-13 gene by a microarray analysis. The association of a PGI2-PPARδ-IL-13 pathway with cellular adhesion is examined, and a fact that the production of the IL-13 mediated by the PPARδ inhibits the adhesion of monocytes with endothelium cells markedly is elucidated. The association between the PGI2-PPARδ-IL-13 pathway and COX (cyclooxygenase)-2 is examined, and it is found that the IL-13 production mediated by PGI2/PPARδ inhibits the expression of the COX-2. It is known that the monocyte-endothelium cell adhesion and COX-2 are related to the inflammation. Therefore, it is possible to use a cell adhesion inhibitor or COX-2 inhibitor by taking the PGI2-PPARδ-IL-13 pathway as the target can be utilized as an anti-inflammatory agent.
COPYRIGHT: (C)2005,JPO&NCIPI
摘要翻译：待解决的问题：以PGI2-PPARδ传输系统为目标，提供PGI2-PPARδ传递系统的靶基因和新的炎性疾病治疗剂的阐释。解决方案：通过微阵列分析发现PG（前列腺素）I2-PPAR（过氧化物酶体增殖物激活受体）δ传递系统的该靶标是IL（白细胞介素）-13基因。检测PGI2-PPARδ-IL-13途径与细胞粘附的关联，并且阐明了由PPARδ介导的IL-13的产生抑制单核细胞与内皮细胞粘附的事实。检测PGI2-PPARδ-IL-13途径与COX（环氧合酶）-2之间的关联，发现由PGI2 /PPARδ介导的IL-13产生抑制COX-2的表达。已知单核细胞 - 内皮细胞粘附和COX-2与炎症有关。因此，可以通过以PGI2-PPARδ-IL-13途径作为靶，可以使用细胞粘附抑制剂或COX-2抑制剂作为抗炎剂。版权所有（C）2005，JPO＆NCIPI

10. 发明专利

NZ523613A Pharmaceutical compositions for angiogenic therapy 未知
公开(公告)号：NZ523613A
公开(公告)日：2005-02-25
申请号：NZ52361301
申请日：2001-06-27
申请人： ANGES MG INC
发明人： MORISHITA RYUICHI , KOIKE HIROMI , TANABE TADASHI , AOKI MOTOKUNI
IPC分类号： A61K31/5585 , A61K31/711 , A61K38/17 , A61K38/52 , A61K48/00 , A61P9/00 , A61P9/10 , A61K45/00 , A61K38/18
摘要： The use of a prostacyclin synthase gene and a HGF gene or a VEGF gene in the preparation of a medicament for angiogenic therapy; wherein the therapy is preferably for treating or preventing ischemic disease of arterial disease such as arteriosclerosis obliterans, myocardial infarction, angina pectoris, cardiomyopathy and cerebrovascular disease.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式